iShares Global Healthcare ETF (IXJ)
| Assets | $3.67B |
| Expense Ratio | 0.41% |
| PE Ratio | 29.44 |
| Shares Out | 47.85M |
| Dividend (ttm) | $1.29 |
| Dividend Yield | 1.50% |
| Ex-Dividend Date | Dec 17, 2024 |
| Payout Ratio | 42.36% |
| 1-Year Return | -0.08% |
| Volume | 133,995 |
| Open | 85.35 |
| Previous Close | 85.66 |
| Day's Range | 85.21 - 86.48 |
| 52-Week Low | 85.21 |
| 52-Week High | 101.31 |
| Beta | 0.65 |
| Holdings | 151 |
| Inception Date | Nov 13, 2001 |
About IXJ
Fund Home PageThe iShares Global Healthcare ETF (IXJ) is an exchange-traded fund that is based on the S&P Global 1200 / Health Care index, a market-cap-weighted index of global health care companies. IXJ was launched on Nov 13, 2001 and is issued by BlackRock.
Top 10 Holdings
43.67% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 8.61% |
| UnitedHealth Group Incorporated | UNH | 6.29% |
| Novo Nordisk A/S | NOVO.B | 4.79% |
| Johnson & Johnson | JNJ | 4.71% |
| AbbVie Inc. | ABBV | 4.34% |
| Merck & Co., Inc. | MRK | 3.56% |
| AstraZeneca PLC | AZN | 2.92% |
| Roche Holding AG | ROG | 2.86% |
| Thermo Fisher Scientific Inc. | TMO | 2.83% |
| Abbott Laboratories | ABT | 2.76% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 17, 2024 | $0.617 | n/a |
| Jun 11, 2024 | $0.672 | Jun 17, 2024 |
| Dec 20, 2023 | $0.556 | Dec 27, 2023 |
| Jun 7, 2023 | $0.644 | Jun 13, 2023 |
| Dec 13, 2022 | $0.440 | Dec 19, 2022 |
| Jun 9, 2022 | $0.551 | Jun 15, 2022 |
News
IXJ: Healthcare Sector Dashboard For November
The healthcare sector is overvalued by 18% relative to 11-year averages, with pharmaceuticals/biotechnology and healthcare equipment most overpriced. IXJ offers global healthcare exposure with lower c...
IXJ: Healthcare Sector Dashboard For August
Monthly article series showing healthcare industry metrics. The healthcare sector is overvalued by about 18% relative to 11-year averages. The most overvalued subsector is pharmaceuticals and biotechn...
IXJ: Growth Expected To Be Very Strong In The Next Few Years
iShares Global Healthcare ETF has underperformed the S&P 500 index in the past few years. IXJ has lower volatility and downside risk compared to the broader market. The healthcare sector is expected t...
IXJ: Healthcare Sector Dashboard For March
The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Gl...
IXJ: Healthcare Dashboard For December
The healthcare sector valuation is close to 11-year averages. Pharmaceuticals/biotechnology and life science tools are close to the historical baseline, while healthcare equipment is the less attracti...
IXJ: Healthcare Dashboard For September
The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attra...
Biden calls IRA ‘one of the most significant laws' ever as he promotes climate investments
President Joe Biden on Wednesday marked the first anniversary of his Inflation Reduction Act, a massive package of climate and healthcare initiatives that is part of his broader “Bidenomics” program.
IXJ: Potential To Generate Steady Price Growth Over The Long Run
As the populations of most wealthy countries continue to age, the healthcare sector is going to benefit irrespective of economic conditions. Investors are continuing to opt for stocks from safer secto...
IXJ: Healthcare Dashboard For April
Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one.
IXJ: Long-Term Buy On Global Healthcare Tailwinds
iShares Global Healthcare ETF has beaten the S&P 500 over the past 5 years while having less volatility. The IXJ ETF is full of high-quality companies and is globally diversified, lowering the risk of...
IXJ Has A Shot At Earnings Growth But Is Still Too Expensive
Earnings growth can happen in this ETF, which is supported by some insurance economics, but also simple demographics and resilient healthcare demand. Earnings growth is hard to come by in current mark...
IXJ Is Resilient But No Strong Angle
IXJ gives you very broad-based healthcare exposure. But the bet isn't narrow enough to provide a strong angle or particularly good value.
IXJ: Healthcare Dashboard For May
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued.
IXJ: A Healthcare ETF For Long Term Hold
After poor performance during 2015 to 2018, IXJ reshuffled its portfolio. Price return in the past 3 years is good and even better in the longer period.
Final Trades: CrowdStrike, Microsoft & more
The "Halftime Report" traders give their top picks to watch for the second half.
Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.
IXJ: Well Poised To Benefit From Macro Tailwinds
IXJ has outperformed its developed market benchmark since its inception. Global healthcare spending, which grew at 2.8% from 2015-2019, is poised to grow at 4% from 2020 to 2024.
Best And Worst Q4 2020: Healthcare ETFs And Mutual Funds
The Healthcare sector ranks eighth in Q4'20. Based on an aggregation of ratings of the 359 stocks in the Healthcare sector.
Best And Worst Q3 2020: Healthcare ETFs And Mutual Funds
Best And Worst Q3 2020: Healthcare ETFs And Mutual Funds
Final Trades: Disney, Seattle Genetics & more
The "Halftime Report" traders give their top picks to watch for the second half.
iShares Global Healthcare ETF: Growth Outlook Is Strong
Stocks in IXJ’s portfolio should benefit from an ageing population in the world.